Brokerages Set Atossa Genetics Inc. (NASDAQ:ATOS) Target Price at $68.33

Atossa Genetics Inc. (NASDAQ:ATOS) has been assigned a consensus rating of “Hold” from the five research firms that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $36.3333.

A number of research analysts have issued reports on the company. Ascendiant Capital Markets reduced their price objective on Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a research note on Wednesday, January 21st. Finally, HC Wainwright boosted their target price on shares of Atossa Genetics to $25.00 and gave the company a “buy” rating in a research note on Thursday, March 26th.

Atossa Genetics Stock Performance

NASDAQ:ATOS opened at $4.94 on Wednesday. The firm has a market cap of $42.54 million, a price-to-earnings ratio of -1.37 and a beta of 1.34. Atossa Genetics has a 52 week low of $3.76 and a 52 week high of $19.35. The firm has a 50-day moving average price of $4.84 and a two-hundred day moving average price of $9.42.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. &PARTNERS bought a new stake in shares of Atossa Genetics in the fourth quarter valued at $25,000. Hudson Bay Capital Management LP bought a new position in shares of Atossa Genetics during the 2nd quarter worth $26,000. Gallagher Capital Advisors LLC bought a new position in shares of Atossa Genetics during the 3rd quarter worth $27,000. JPMorgan Chase & Co. grew its stake in shares of Atossa Genetics by 1,294.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after acquiring an additional 35,474 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of Atossa Genetics by 55.7% during the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after acquiring an additional 35,629 shares during the period. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.